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A clear understanding of the antiviral effects of CD8 T cells in the context of chronic human immunode-
ficiency virus (HIV) infection is critical for the development of prophylactic vaccines and therapeutics designed
to support T-cell-mediated immunity. However, defining the potential correlates of effective CD8 T-cell
immunity has proven difficult; notably, comprehensive analyses have demonstrated that the size and shape of
the CD8 T-cell response are not necessarily indicative of efficacy determined by measures of plasma viral load.
Here, we conducted a detailed quantitative and qualitative analysis of CD8 T-cell responses to autologous
virus in a cohort of six HIV-infected individuals with a history of structured interruption of antiretroviral
therapy (ART) (SIT). The magnitude and breadth of the HIV-specific response did not, by themselves, explain
the changes observed in plasma virus levels after the cessation of ART. Furthermore, mutational escape from
targeted epitopes could not account for the differential virological outcomes in this cohort. However, the
functionality of HIV-specific CD8 T-cell populations upon antigen encounter, determined by the simultaneous
and independent measurement of five CD8 T-cell functions (degranulation and gamma interferon, macro-
phage inflammatory protein 1, tumor necrosis factor alpha, and interleukin-2 levels) reflected the emergent
level of plasma virus, with multiple functions being elicited in those individuals with lower levels of viremia
after SIT. These data show that the quality of the HIV-specific CD8 T-cell response, rather than the quantity,
is associated with the dynamics of viral replication in the absence of ART and suggest that the effects of SIT
can be assessed by measuring the functional profile of HIV-specific CD8 T cells.
The dynamics of human immunodeficiency virus type 1
(HIV-1) infection are influenced, in part, by the ability of
virus-specific CD8 T-cell responses to control initial viremia
following acute HIV-1 infection and suppress viral replication
during the chronic phase of infection. There are several lines of
evidence that support a critical role for the antiviral effects
mediated by HIV-specific CD8 T cells. First, the appearance
of cytotoxic CD8 T lymphocytes (CTLs) during acute infec-
tion coincides with a decrease in plasma viremia, and con-
versely, the experimental depletion of CD8 T cells in vivo
results in a rapid increase in plasma viremia in the simian
immunodeficiency virus macaque model (15, 32, 37, 53). Sec-
ond, several HLA class I alleles are consistently linked to
differential outcomes (17); for example, strong virus-specific
CTL responses restricted by HLA-B*57 are typically associ-
ated with slower disease progression in HIV infection (34, 42,
44). Third, the selective immune pressure exerted on the viral
genome by CTLs has been supported by studies demonstrating
viral escape at targeted epitopes in HIV-1 and simian immu-
nodeficiency virus infection (29, 49, 50). In addition, longitu-
dinal studies of humans have demonstrated that mutational
escape from CTL-mediated immune responses can be associ-
ated with progressive increases in HIV plasma viremia (26,
33, 48).
Despite the cumulative evidence demonstrating a crucial
role for the antiviral effects of CD8 T cells, the identification
of consistent quantitative and qualitative correlations remains
an elusive goal. Detailed studies comparing the breadths and
magnitudes of CD8 T-cell responses in infected persons have
failed to show a relationship between these parameters and
viral load (1, 8). Moreover, despite the initially promising pres-
ervation and enhancement of HIV-specific CD8 T-cell re-
sponses during acute infection with early initiation of antiret-
roviral therapy (ART) (46, 51), attempts to boost immune
responses therapeutically, for example, through autovaccina-
tion in the setting of ART interruptions in chronic HIV infec-
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tion, have proven disappointing (5, 22–24, 45, 47, 52). More
recent studies have suggested that functional attributes of
CD8 T-cell responses in individuals with chronic HIV-1 in-
fection might help to discriminate differential virological out-
comes (7, 12, 13, 40, 41, 43), but whether there are epitope-
specific differences in functional immune responses and the
extent to which immune escape complicates this picture during
chronic infection are not known.
In this study, we performed a detailed analysis of the quan-
titative and qualitative differences observed in HIV-specific
CD8 T-cell responses to autologous virus after a definitive
cessation of ART in HIV-infected individuals with a history of
structured interruption of therapy (SIT). Our results demon-
strate substantial variations in the magnitudes and breadths of
the HIV-specific T-cell responses for each individual tested;
however, no correlation between viral load and either fre-
quency or breadth of the cellular immune response following
the cessation of therapy was found. Moreover, the observation
of limited viral evolution within immunodominant epitopes
targeted by CD8 T cells during SIT and the post-SIT period
suggests that immune escape did not directly influence either
the HIV-specific T-cell response or virological outcome after
SIT. However, the functional profile of HIV-specific CD8 T
cells did provide a clearer association with virological outcome,
especially in the case of individuals experiencing low levels of
plasma viremia for extended periods off ART.
MATERIALS AND METHODS
Patient characteristics, antiretroviral treatment regimens, and clinical assays.
Enrollment criteria for the SIT protocol, as previously described (21), were
documented HIV infection with a CD4 T-cell count of 300 cells/mm3 and
plasma HIV RNA levels of 50 copies/ml during screening and 500 copies/ml
for 6 months on a potent ART regimen comprised of a protease inhibitor
(indinavir [IDV] or nelfinivir) combined with a nonnucleoside reverse transcrip-
tase inhibitor (nevirapine [NVP] or efavirenz) and/or a nucleoside reverse tran-
scriptase inhibitor (NRTI) (stavudine [d4T], didanosine, or lamivudine [3TC]).
The study was designed for 90 patients randomly assigned to continue ART or
receive seven cycles of 4 weeks without ART followed by 8 weeks with ART.
However, the study was prematurely terminated due to a high failure rate in the
SIT arm after 26 patients in each arm were enrolled (21). Six of the 26 individuals
from the treatment interruption arm voluntarily underwent a final cessation of
ART after 92 weeks of SIT. Four of these individuals received a three-drug ART
regimen during SIT consisting of a protease inhibitor (IDV or NVP) and two
NRTIs (3TC and d4T); one individual received a combination of 3TC, d4T, and
NVP; and one individual received IDV, zidovudine-3TC (Combivir), and
efavirenz. All patients were monitored every 4 weeks for changes in plasma HIV
RNA load as determined by branched DNA (limit of detection, 50 copies/ml)
(Quantiplex bDNA assay; Bayer, Norwood, MA) and lymphocyte subsets, in-
cluding activation status, by standard flow cytometric techniques. Immunologic
characteristics of the participants are provided in Table 1. Patients with a viral
load of 50,000 copies/ml on two consecutive tests or with mean CD4 T-cell
counts 25% lower than the mean of enrollment values on two consecutive
determinations returned to continuous ART.
Peptides. Peptide pools consisted of individual 15-mer peptides overlapping by
11 amino acids and were based on sequences derived from clade B chimeric HIV
strain HXBc2/Bal R5 (Gag, Pol, Env, or Nef) and HIV strain SF2 (Tat, Rev, Vif,
Vpr, and Vpu) (NIH AIDS Research and Reference Program). Total HIV-
specific T-cell responses were determined using these pools at a concentration of
2 g/ml with respect to each individual peptide. Overlapping 15-mer peptides
were also grouped together in pools according to antigen; a total of 122 peptides
in 23 pools for Gag and 49 peptides in 14 pools for Nef were used in a matrix
format at the above-mentioned concentration per peptide to identify and quan-
tify CD8 T-cell responses specific for individual epitopes. Subsequent optimal
peptide-mapping experiments were performed using a panel of 11-mer peptides
overlapping by 10 amino acid residues. Peptides were synthesized as free acids
(Mimetopes PTY, Inc., NC) at a purity of 95% and reconstituted in 100%
high-performance liquid chromatography-grade dimethyl sulfoxide at a concen-
tration of 100 mg/ml.
Antibodies. Directly conjugated antibodies for flow cytometric analysis were
used in the following fluorochrome combinations available from commercial
sources: (i) IL-2 (interleukin-2)–allophycocyanin (APC), IL-2–phycoerythrin
(PE), CD3-Cy7-APC, CD4-peridinin chlorophyll protein, gamma interferon
(IFN-)-fluorescein isothiocyanate (FITC), IFN-–PE, tumor necrosis factor
alpha (TNF-)–PE, macrophage inflammatory protein 1 (MIP1)-PE, CD14-
Cy5-PE, CD19-Cy5-PE, and TNF-–Cy7–PE (BD Biosciences, CA); (ii) CD4-
Cy5.5-PE (Caltag, CA); and (iii) CD45RO-Texas Red-PE (Beckman Coulter,
CA). The following antibodies were conjugated in our laboratory according to
standard protocols: CD8-Qdot 705, CD27-Cascade Blue, CD57-Qdot 565, and
CD107a-Alexa 680. The corresponding unconjugated monoclonal antibodies
were obtained from BD Biosciences. Cascade Blue and Alexa 680 were obtained
from Molecular Probes (Eugene, OR); quantum dots were obtained from the
Quantum Dot Corporation (Hayward, CA).
Functional quantification of HIV-specific T cells. Frozen peripheral blood
mononuclear cells (PBMCs) were thawed, resuspended at 5  106 cells/ml in
complete medium (RPMI medium supplemented with 10% heat-inactivated
fetal bovine serum, 100 U/ml penicillin G, 100 g/ml streptomycin sulfate, and
1.7 mM sodium glutamate), added to 96-well V-bottom plates (Costar Inc., NY)
in 200-l aliquots (1  106 cells), and rested overnight at 37°C in 5% CO2. For
individual peptide or peptide pool stimulations, costimulatory antibodies (anti-
CD28 and anti-CD49d at a final concentration of 1 g/ml; BD Biosciences, CA)
and brefeldin A (final concentration of 10 g/ml; Sigma Aldrich, MO) were
added to the cells; HIV peptides were added at a concentration of 2 g/ml, and
the cells were incubated for 6 h. A negative control (costimulation alone) and a
positive control (Staphylococcus enterotoxin B at a final concentration of 1
g/ml; Sigma Aldrich, MO) were included in each assay. After peptide stimula-
tion, PBMCs were washed once with fluorescence-activated cell sorter buffer
(1% fetal bovine serum albumin, 0.1% sodium azide) and stained with anti-CD3-
APC, anti-CD4-peridinin chlorophyll protein, and anti-CD8-FITC. The cells
were then washed again, fixed and permeabilized using 200 l of 2 fixation-
permeabilization solution (Becton-Dickinson Immunocytometry Systems, San
Jose, CA), washed two further times, and then stained with antibodies to the
cytokines IFN-, TNF-, and IL-2 (all directly conjugated to PE). After staining,
TABLE 1. Immunological characteristics of HIV-infected individuals during and after SIT
Patient HLA serotypes Baseline CD4 countprior to SIT
Nadir CD4
counta
Mean absolute T-cell count
During SITb After SITc
CD4 CD8 CD4 CD8
101 A2, A3, B7, B15, Cw3, Cw6 415 257 367 1,010 320 925
102 A3, A29, B7, B44, Cw3, Cw7 1,419 453 1,201 804 1,098 729
103 A2, A24, B7, B40, Cw3, Cw6 581 246 559 571 462 448
114 A24, A25, B7, B18, Cw7, Cw12 1,090 426 1,031 801 824 1,022
119 A3, A24, B7, B8, Cw7 451 150 434 1,265 413 1,266
124 A1, A2, B40, B57, Cw3, Cw6 1,104 311 888 853 827 744
a Lowest measurable CD4 count.
b Mean absolute T-cell counts during SIT (seven cycles of 8 weeks on/4 weeks off ART).
c Mean absolute T-cell counts during final cessation of ART after SIT (study week 92).
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the cells were washed a final time and resuspended in 1% paraformaldehyde
(Electron Microscopy Systems, Fort Washington, PA) in phosphate-buffered
saline. Six-parameter flow cytometric analysis was performed using a FACSCali-
bur flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose,
CA). Between 150,000 and 200,000 events were collected for each sample.
Cytokine expression was calculated following subtraction of background (anti-
CD28/49d alone).
Functional profiling of HIV-specific T cells by polychromatic flow cytometry.
Purified PBMCs were thawed, resuspended at 2  106 cells/ml in complete
medium, and rested overnight at 37°C with DNase I (10 U/ml; Roche Diagnos-
tics, Indianapolis, IN). The following day, PBMCs were examined for viability
and adjusted to 1  106 cells/ml. Costimulatory molecules (anti-CD28 and
anti-CD49d), monensin (0.7 l/ml; BD Biosciences), brefeldin A, and anti-
CD107a-Alexa 680 (pretitered volume) were added; cells were then aliquoted at
1 ml to each tube containing 5 l of peptide mixes (2-g/ml final concentration
for each individual constituent peptide) representing the HIV Gag and Nef
protein sequences. An unstimulated control and a positive control (Staphylococ-
cus enterotoxin B) were included in each assay. Cells were incubated for 6 h at
37°C. Following incubation, the cells were washed with fluorescence-activated
cell sorter buffer and stained with the following surface antibodies: CD3-Cy7-
APC, CD4-Cy5.5-PE, CD8-Qdot 705, CD27-Cascade Blue, and CD45RO-Texas
Red-PE. The cells were then washed and fixed. Following fixation, the cells were
washed twice in perm buffer and stained with the following intracellular anti-
bodies: IL-2–APC, TNF-–Cy7–PE, MIP1-PE, and IFN-–FITC (BD Bio-
sciences). After a further wash, cells were fixed, and data were acquired imme-
diately. Polychromatic flow cytometric analysis was performed using an LSRII
flow cytometer (Becton Dickinson, San Jose, CA). At least 300,000 live lympho-
cytes were collected, and list-mode data files were analyzed using FlowJo, version
6.3.1 (Tree Star Inc., Ashland, OR). The gating strategy was initially set to
eliminate cell doublets according to forward-scatter area-versus-height proper-
ties. Subsequently, dead cells (Cascade Blue bright) and CD14/CD19 cells
were gated out against side scatter, and lymphocytes were selected according to
standard light scatter properties after confirming that any functional response
originated from this population. Functional capacity was determined after Bool-
ean gating, and subsequent analysis was performed using Simplified Presentation
of Incredibly Complex Evaluations (version 2.9; Mario Roederer, VRC, NIAID,
NIH) (13). All values used for analyzing a proportionate representation of
responses were background subtracted. Nonspecific background was extremely
low when combinations of functions were examined. With single functions, es-
pecially MIP1, backgrounds were occasionally higher; stringent gating strate-
gies were therefore used to ensure that only MIP1-bright T cells were included
in the analysis (13).
Sequencing of autologous virus. HIV virions were concentrated from 1 ml of
plasma by centrifugation at 17,530  g for 75 min at 4°C. The supernatant was
removed, and the pellet was resuspended in 1 ml of Trizol-LQ (Invitrogen). Viral
RNA was extracted according to standard protocols, and cDNA was prepared
using the Superscript first-strand synthesis system with a mixture of random
hexamers and oligo(dT). A two-step nested PCR amplification of the viral cDNA
was performed using Platinum Taq polymerase (Invitrogen); outer and inner
primer sets for HIV gag, pol, env, and nef were designed and used as previously
described (4). Amplification products were gel purified and cloned using the
TOPO TA cloning kit (Invitrogen). Plasmids were transformed into competent
Top10 F	 Escherichia coli cells (Invitrogen). Individual clones were screened
using X-gal (5-bromo-4-chloro-3-indolyl--D-galactopyranoside) complementa-
tion, and colony DNA was prepared using Qiagen Miniprep kits. Clones were
sequenced bidirectionally on an ABI 3100 Prism automated sequencer and
assembled using Sequencher, version 4.5 (GeneCodes Inc., Ann Arbor, MI). At
least 10 clones were sequenced for each PCR product, and the autologous viral
sequence was compared to the consensus HxB2 sequence.
RESULTS
Virological and immunological characteristics of SIT pa-
tients following cessation of ART. Six of 26 chronically infected
patients who received SIT comprising at least seven cycles of 4
weeks off ART followed by 8 weeks on ART underwent a
definitive interruption of therapy at study week 92 (end of the
last cycle on therapy) (21). Plasma viremia and T-cell subset
counts were monitored during the course of SIT and the drug
cessation period (Fig. 1). Individuals resumed ART if their
HIV plasma loads exceeded the clinical failure criteria of
50,000 copies/ml on two consecutive tests or 10,000 cop-
ies/ml on three consecutive tests or if their mean CD4 T-cell
count on two consecutive determinations was 25% lower than
the mean of the screening and enrollment values. Relatively
stable CD4 and CD8 T-cell counts were observed for each
individual during SIT and the post-SIT period off ART (Table 1).
All six individuals experienced a rebound in plasma viremia
after the cessation of ART and maintained various levels of
detectable plasma HIV RNA levels throughout the final drug
interruption period (Fig. 1). The virological characteristics are
summarized in Table 2. To test for predictors of the virological
response after cessation of ART, the mean plasma viral load
(pVL) off therapy (after SIT) was compared to the pVL at SIT
cycle 1, at week 4 off ART (Fig. 1). Previous findings from SIT
pilot studies suggested that rebounding virus during the first
off-drug cycle is a reasonable predictor of pretreatment viral
set point (45, 47). The duration off ART was used as a sec-
ondary predictor because longer periods off therapy suggest a
more favorable virological response. For each patient, the pla-
teau pVL was defined as the mean (geometric) pVL during the
post-SIT period (median number of measurements, 8; range, 2
to 13). The mean time off therapy was 26 weeks (median, 33
weeks; range, 8 to 52 weeks). All six individuals experienced
pVLs off ART that were lower than the estimated viral set
point determined from cycle 1, at week 4 off ART. Two indi-
viduals (patients 101 and 114) developed especially favorable
virological responses during the post-SIT period, while one
individual (patient 124) experienced a more modest response
(Table 2). The least favorable virological outcomes were ob-
served for patients 102, 103, and 119. Patient 119 experienced
a minimal reduction in mean pVL off ART (6.11-fold) and
returned to therapy after 12 weeks off ART due to three
consecutive viral load measurements of 10,000 copies/ml. In
contrast, patient 102 remained off ART for the longest period
of time (52 weeks), despite having the smallest reduction be-
tween levels of viremia post-SIT and the estimated viral set
point (Table 2). Patient 103 was off ART for 8 weeks and
recommenced continuous therapy after two consecutive pVL
measurements of 50,000 HIV RNA copies/ml. It should be
noted that this individual entered the SIT study with genotypic
resistance to efavirenz (K170R). The mutation was not de-
tected until week 60 of SIT. At this time, the ARV regimen was
changed to zidovudine-3TC-IDV, and the individual continued
to the end of the SIT period and elected to halt ART. At week
96, the additional resistance mutations D76N (NRTI) and
K70R (NRTI) were detected.
Relationship between the magnitude of the HIV-specific im-
mune response and virological outcome in SIT-experienced
patients following cessation of ART. Quantitative aspects of
the HIV-specific immune response, defined by magnitude and
breadth, have frequently been used in attempts to define the
correlates of T-cell efficacy in relation to pVL (1, 10, 16, 47). In
order to assess whether the magnitude of the total HIV-spe-
cific immune response was an immunologic predictor of pla-
teau pVLs observed during the off-ART period following SIT,
CD4 and CD8 T-cell responses to different viral proteins
were quantified by flow cytometry according to direct ex vivo
cytokine (IFN-, TNF-, and IL-2) production upon stimula-
tion with peptide pools spanning the consensus HIV-1 Gag,
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Pol, Nef, Env, Rev, Tat, Vpu, Vpr, and Vif proteins. HIV-
specific CD4 and CD8 T-cell responses were measured at
week 84 (start of final on-ART cycle) and at one or more
further time points during the final cessation of therapy. A
heterogeneous pattern of T-cell responses was observed with
representative patient profiles shown in Fig. 2. In general, total
HIV-specific CD4 T-cell responses were lower in magnitude
than CD8 T-cell responses, and responses to Gag and Nef
peptides were immunodominant in the CD8 T-cell popula-
tions. Patients 101 and 114, considered to be the best respond-
ers virologically, showed substantial increases in the magni-
tudes of their HIV-specific CD8 T-cell responses. The
immunodominant CD8 T-cell target protein in patient 101
was Gag, while the corresponding responses in patient 114
targeted primarily Nef. Interestingly, the lowest-magnitude T-
cell responses were observed in patient 102, despite the main-
tenance of a mean pVL of 4,778 copies/ml for at least 52 weeks
off therapy. Of note, two of the three individuals with the
poorest virological response post-SIT (patients 103 and 119)
also developed potent HIV-specific CD8 T-cell responses.
These data suggest that the magnitude of the HIV-specific
T-cell response alone is insufficient to predict virological out-
come in these individuals.
Relationship between the breadth of HIV-specific T-cell re-
sponses and virological outcome. To quantify the breadth of the
HIV-specific CD8 T-cell response, a peptide matrix comprising
23 pools (122 total peptides) of 15-mer peptides overlapping by 11
amino acids for Gag was used to stimulate PBMCs directly ex vivo
from multiple time points during treatment interruption for all six
individuals. In addition to Gag, a Nef matrix comprising 14 pools
of peptides (49 total 15-mer peptides) was used to stimulate cells
from patient 114. A complete summary of the matrix peptide
analysis is shown in Table 3. Overall, no consistent patterns were
observed to relate the breadth of the HIV-specific T-cell response
with virological outcome.
Of the two individuals with the highest-magnitude HIV-
specific CD8 T-cell responses, a broad response was observed
in patient 101, with CD8 T cells recognizing a total of 18
peptides corresponding to Gag p17 (positions 1 to 35), p24
(positions 265 to 303), and p24 (positions 309 to 347), and a
narrow response was observed in patient 114, with CD8 T
cells targeting a single peptide, LKETINEEAAEWDRV, in
FIG. 1. Immunological and virological characteristics of HIV-infected individuals during SIT and definitive cessation of ART. A cohort of six
individuals with chronic HIV infection received SIT comprised of 8 weeks on ART followed by 4 weeks off ART for a period of up to 92 weeks.
At week 92 of the study, individuals voluntarily stopped ART. Viral load (HIV RNA copies/ml plasma) and absolute numbers of CD4 and CD8
T cells per mm3 of blood were monitored throughout treatment interruption and cessation periods. Gray shading depicts periods on ART. Patients
103, 119, and 124 restarted ART at weeks 100, 104, and 117, respectively.
TABLE 2. Virological characteristics of HIV-infected individuals
during and after SIT
Patient Viral set point(HIV copies/ml)a
Mean pVL after
SITb (HIV
copies/ml)
Time off
ART (wk)
Fold reduction
in viral set
point versus
no ART
101 127,125 4,660 40 27.28
102 11,068 4,778 52 2.32
103 57,794 21,888 8 2.64
114 241,785 3,956 40 61.12
119 165,152 27,045 12 6.11
124 76,390 4,458 25 17.14
a Viral set point (estimate) is pVL at week 4 off ART of the first SIT cycle.
b Geometric mean.
VOL. 82, 2008 VIROLOGIC OUTCOME AND CD8 T-CELL FUNCTIONALITY 4105
 o
n
 February 25, 2014 by Cardiff Univ
http://jvi.asm.org/
D
ow
nloaded from
 
Gag p24 (positions 201 to 217) and a single region in Nef. A
narrow, low-frequency CD8 T-cell response to one peptide in
Gag was observed for patient 124, despite a relatively favorable
virological response off therapy.
The breadths of the HIV-specific immune response in indi-
viduals with poorer virological outcomes also varied. Cytokine-
producing CD8 T cells from patient 119 recognized six pep-
tides from Gag, while patient 102 exhibited a low-frequency
CD8 T-cell response narrowly directed to three overlapping
peptides in Gag p17 (positions 1 to 31). For patient 103, the
individual with the worst virological outcome post-SIT, the
CD8 T-cell response was the broadest compared to all other
individuals, with a total of 24 peptides from four separate
regions of Gag being recognized (Table 3). Thus, the high
degree of variability in the breadth and magnitude of the HIV-
specific CD8 T-cell responses observed between SIT-experi-
enced individuals with different pVL plateaus off ART suggests
that these quantitative aspects of the immune response do not
correlate with virological outcome.
Functionality as a qualitative measure of T-cell responses to
targeted HIV proteins. Emerging evidence suggests that qual-
itative, rather than quantitative, aspects of the HIV-specific
T-cell response may be better correlates of virological changes
that occur in the absence of ART (11, 13, 18, 30). To assess
whether there were differences in HIV-specific CD8 T-cell
functionalities between individuals with different virological
outcomes, HIV-specific CD8 T-cell populations were stimu-
lated with the relevant targeted antigens (Gag or Nef) and
analyzed by polychromatic flow cytometry to examine multiple
functional readouts. Specifically, the following effector func-
tions were assessed simultaneously and independently: CD8
T-cell degranulation, determined by CD107a mobilization; the
production of the cytokines IFN-, TNF-, and IL-2; and the
production of the chemokine MIP1. Following the stimula-
tion of unfractionated PBMCs with HIV Gag or Nef peptide
mixtures, the expression of each functional marker was exam-
ined after stringent gating on CD8 T cells as described pre-
viously (13). A Boolean algorithm yielding 32 unique response
patterns comprising every combination of the five individual
measurements (CD107a, IFN-, MIP1, TNF-, and IL-2)
was applied to the gated cells. The frequency of each of these
individual response patterns was then calculated, and the con-
tribution of each combination to the total response was deter-
mined (Fig. 3).
Polyfunctionality was most apparent in the HIV-specific
CD8 T-cell populations from the individuals who maintained
low levels of plasma viremia during the post-SIT period. The
majority of the Gag-specific CD8 T cells in patient 101 and
Nef-specific CD8 T cells in patient 114 expressed a combi-
nation of “3” and “4” functions (Fig. 3). Furthermore, a
FIG. 2. Magnitude of the total HIV-specific T-cell response. The total magnitudes of the CD4 (A) and CD8 (B) T-cell responses determined
using mixes of overlapping peptides specific for Gag, Pol, Env, Nef, and Rev and Tat, Vpu, Vpr, and Vif (RTVV) are shown for each subject as
the percent cytokine production during the first week of the last cycle on ART (week 84) and subsequent time points after the cessation ART.
Levels of pVL are shown as log10 HIV RNA copies/ml. Overall, the magnitude of the total HIV-specific T-cell response was not predictive of
virological outcome.
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proportion of HIV-specific CD8 T cells in individuals with a
good virological outcome were positive for all five functions
measured (Fig. 3); this high degree of functionality was ob-
served previously in long-term nonprogressors (13). Interest-
ingly, when the functional profiles of Gag- and Nef-specific
CD8 T-cell populations from patient 114 were compared, the
Gag-specific CD8 T-cell response was lower not only in mag-
nitude but also in functionality than the Nef-specific response,
suggesting a relationship between functionality and immu-
nodominance (Fig. 3).
In patient 102, a polyfunctional pattern similar to those of
patients 101 and 114 was observed. There was a modest reduction
in plasma viremia off ART compared to the viral set point in this
individual and a low-frequency Gag-specific CD8 T-cell re-
sponse; however, the length of time without therapy (52 weeks)
may provide an additional virological factor that associates with
the polyfunctional nature of the HIV-specific CD8 T-cell re-
sponse. For patients 119 and 124, the majority of the Gag-specific
response was composed primarily of cells expressing two func-
tions or less. The most monofunctional CD8 T-cell response was
observed for patient 124 despite a relatively good virological out-
come. Further monofunctionality was observed in CD4 T-cell
populations from all six patients analyzed. However, the low fre-
quency of the total HIV-specific response in this T-cell subset
made it technically difficult to determine a relationship with viral
outcome (data not shown). The degree of functionality is more
clearly evident when the CD8 T-cell responses from all func-
tional combinations within a group are summed together (Fig. 4).
Despite variations in frequency, the dominant responses in pa-
tients 114, 101, and 102 exhibited a higher degree of functionality
than the responses observed in patients 119 and 124. Further cells
from patient 103 were not available for analysis.
Memory phenotyping of polyfunctional CD8 T-cell popu-
lations according to CD27, CD45RO, and CD57 expression
failed to reveal any consistent patterns that could add discrim-
inatory power to our analyses; indeed, substantial phenotypic
heterogeneity was apparent within the polyfunctional HIV-
specific CD8 T-cell subset (data not shown).
Despite the limited number of patients in this study, the
observation that a higher degree of virus-specific CD8 T-cell
functionality prevails in individuals with reduced levels of
plasma viremia in the absence of ART suggests that qualitative
aspects of the HIV immune response may help predict viro-
logical outcome after SIT. It remains to be determined
whether this relationship is causal.
Viral sequence variation and immune recognition within
targeted CD8 T-cell epitopes. The mutability of HIV, espe-
cially in the absence of ART, can enable the virus to escape
immune surveillance through alterations in antigen presenta-
tion and recognition. An effective HIV-specific CD8 T-cell
response, however, may be sufficient to suppress viral replica-
tion and limit the emergence of escape mutations. It is possi-
ble, therefore, that SIT individuals with poorer virological out-
comes in the absence of therapy have developed escape
mutations capable of subverting the HIV-specific CD8 T-cell
response. To determine the extent of sequence variation in
targeted viral epitopes during the SIT and post-SIT periods,
and to measure the ability of HIV-specific CD8 T cells to
recognize these epitopes, longitudinal sequence analysis of
plasma virus RNA followed by high-resolution peptide map-
ping was performed. Changes that emerged within stretches of
sequences containing one or more CD8 T-cell epitopes are
shown in Fig. 5. Despite various levels of rebounding plasma
virus over the SIT period, most immunodominant epitope re-
gions failed to show evidence of significant sequence variation.
In addition, the emergence of new variants was not observed
during the post-SIT period when pVL was slowly increasing or
plateauing. Sequence analysis of molecular clones derived
from HIV proviral DNA from patients 101 and 114 confirmed
the presence of viral variants similar to those found in the
plasma (data not shown); this suggests that archived virus had
TABLE 3. Summary of the breadth of the CD8 T-cell response after SITa
Patient No. of peptidesb Amino acid sequence Frequencyc Protein Positions
103 6 LRPGGKKKYKLKHIVWASRELERFAVNPGLL 0.658 Gag p17 21–51
6 QPSLQTGSEELRSLYVNTAVATLYCVHQRIE 0.644 Gag p17 65–93
6 AMQMLKETINEEAAEWDRVHPVHAGPIAPGQ 0.689 Gag p24 197–227
6 DCKTILKALGPAATLEEMMTACQGVGGPGHK 0.741 Gag p24 329–359
101 6 MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIV 0.689 Gag p17 1–35
6 WIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKT 0.698 Gag p24 265–303
6 ASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMM 0.745 Gag p24 309–347
119 3 LDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGL 0.854 Gag p24 13–50
2 LLVQNANPDCKTILKALGP 0.709 Gag p24 321–339
1 EEMMTACQGVGGPGH 0.629 Gag p24 344–359
114 1 LKETINEEAAEWDRV 1.238 Gag p24 201–217
2 IHSQRRQDILDLWIYHTQGYF 1.455 Nef 101–121
102 3 MGARASVLSGGLEDRWEKIRKLRPGGKKKYKL 0.154 Gag p17 1–31
124 1 EKAFSPEVIPMFSAL 0.188 Gag p24 161–175
a Patient responses are listed from broadest to narrowest.
b Number of peptides indicates the number of matrix peptides defining an epitope region.
c Frequency indicates the mean cytokine response of matrix peptide(s) per epitope region.
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not changed significantly during SIT with attendant periods of
substantial viral replication.
High-resolution epitope-mapping experiments were per-
formed with saturating concentrations of synthetic peptides
consisting of individual 11-mer peptides overlapping by 10
amino acids. Peptides were derived from autologous and con-
sensus HxB2 virus sequences (http://hiv-web.lanl.gov) for each
HIV epitope region included in the sequence analysis (Fig. 5).
The pattern of targeted CD8 T-cell epitopes observed in
individuals who responded well during the post-SIT period
consisted of high-frequency responses to multiple HLA class
I-restricted epitopes within and between immunodominant re-
gions. A list of optimal CD8 T-cell epitopes and their HLA
class I restrictions is shown in Table 4.
In patient 101, the highest-frequency CD8 T-cell responses
were directed against two separate immunodominant regions
in Gag containing the known epitopes HLA A3 [KIRLRPGG
K(18-26)] (KK9), HLA A3/B7 [RLRPGGKKK(20-28)] (RK9),
and HLA B7 [RPGGKKKYK(22-30)] in p17. The KK9 and RK9
epitopes were previously reported for individuals with nonpro-
gressive disease (31) and individuals treated early during acute
infection (2). An escape mutation identified in individuals dur-
ing acute infection was not found within the autologous virus
pool from patient 101 (2, 56). In addition, the KK9 and RK9
FIG. 3. Functional characterization of HIV-specific CD8 T-cell populations during the cessation of ART. PBMCs from patients 101 (week
124), 102 (week 112), and 114 (week 124) (A) and from patients 119 (week 100) and 124 (week 100) (B) were stimulated for 6 h with the relevant
peptides and stained with a panel of monoclonal antibodies to examine degranulation (CD107a), cytokine production (IFN-, TNF-, and IL-2),
and chemokine production (MIP1). The 31 possible positive responses that can be discerned from the simultaneous examination of these five
functional parameters are shown on the x axis and are color-coded according to the number of functions expressed per group. The total frequency
of CD8 T cells displaying each particular functional profile is shown on the y axis.
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epitopes appeared to be recognized by virus-specific CD8 T
cells from patient 102 and patient 119, even though these
individuals had different functional profiles and virological out-
comes off ART.
In patient 114, virus-specific CD8 T cells targeted the
highly conserved p24 Gag epitope ETINEEAAEW(203-212)
(EW10) that is restricted by the HLA-A25 allele (35) and
conserved epitopes in Nef with overlapping HLA-restriction to
A, B, and C alleles (Fig. 5 and Table 4). Interestingly, while
responses to consensus and autologous viral variants were sim-
ilar in magnitude for the EW10 Gag epitope, the autologous
variants targeted in Nef elicited higher-frequency responses
than consensus peptides. For example, the autologous HLA
A24-restricted Nef epitope IYSQKRQDI(101-109) (II9A) was
exclusively targeted over the consensus IHSQKKQDI(101-109)
(II9) epitope. Previous studies demonstrated that the optimal
anchor residues for binding to HLA A24 molecules are ty-
rosine (Y), phenylalanine (F), tryptophan (W), and methio-
nine (M) at position 2 and F, leucine (L), isoleucine (I), and W
at the carboxy terminus of the 9-mer peptide (36, 38). There-
fore, it is possible that an amino acid change from histidine (H)
to Y within the autologous II9 epitope alters the affinity of the
HLA class I-peptide interaction. A similar pattern of immu-
nodominant CD8 T-cell recognition was observed for the
FIG. 4. Functional profiles of HIV-specific CD8 T-cell populations. Individual combinations specific for each functional category (5, 4,
and 3, etc.) are expressed as a percentage of the total response and ordered from highest functionality to lowest. The majority of Gag- and
Nef-specific CD8 T cells from the immunodominant populations in patients 101 and 114, respectively, expressed predominantly 4 and 3
functions, as did patient 102. In contrast, Gag-specific CD8 T cells from patients 119 and 124 had more limited functionality; the subdominant
Gag-specific CD8 T-cell population from patient 114 exhibited similarly restricted functionality.
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FIG. 5. Sequence evolution and recognition of targeted epitopes by HIV-specific CD8 T cells. Longitudinal sequence analyses of immuno-
genic regions showed limited evolution within viral populations during SIT and the post-SIT period off ART. HIV-specific CD8 T-cell recognition
of viral epitopes was determined using overlapping 11-mer peptides offset by 1 amino acid from consensus and autologous sequences for each
targeted region. Only the dominant viral epitopes are shown for clarity. CD8 T cells from patients 101 and 114 recognized multiple HIV epitopes
restricted by different HLA class I alleles. Of note, the highest-frequency responses consistently targeted autologous over consensus peptides.
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HLA B18 [QDILDLWIY(107-115)] and HLA Cw7 [DILDL
WIY(108-115)] epitopes. The autologous variant (I changed to V
immediately prior to the C terminus) (Table 4) for each HLA
allele was again recognized exclusively over the consensus se-
quence. These data confirm previous studies suggesting that
autologous epitopes are recognized at higher frequencies than
consensus peptides (3, 20). More importantly, it appears that
immunodominant CD8 T-cell recognition in two individuals
with favorable virological outcomes occurs within multiple
conserved regions of Gag (patient 101) or Nef (patient 114),
restricted by distinct HLA alleles. In individuals with poorer
virological outcomes (patients 102, 124, and 119), CD8 T-cell
recognition of optimal epitopes occurred at much lower fre-
quencies overall and perhaps with a lesser degree of “epitope
overlap” (Table 4 and Fig. 5). However, in the absence of any
significant evidence for mutational immune escape in any of
the individuals studied here, it is difficult to invoke a role for
such targeting patterns in relation to virological outcome.
DISCUSSION
In this study, we examined quantitative and qualitative as-
pects of the HIV-specific CD8 T-cell response during and
after SIT to define the immunologic associates of virological
outcome. The principal findings were (i) that the magnitude
and breadth of the HIV-specific CD8 T-cell response was
unable to account for differences in viremic control, (ii) that
significant sequence evolution within immunodominant tar-
geted CD8 T-cell epitopes over time did not occur regardless
of virological outcome, and (iii) that the range of effector
functions elicited by CD8 T cells in response to antigen en-
counter was associated with the control of viral replication
after cessation of ART.
Recent advances in immunotechnology have allowed a more
comprehensive quantitative assessment of the magnitude and
breadth of the HIV-specific immune response (1, 8, 9, 14). In
addition, the use of matrices composed of overlapping pep-
tides derived from HIV consensus or autologous viral se-
quences has enabled detailed analyses of CD8 T-cell speci-
ficity in conjunction with sensitive quantitative techniques (1, 3,
14, 55). However, despite this enhanced ability to characterize
HIV-specific T-cell responses directly ex vivo, neither pan-
genomic analyses nor more specific epitope-centered studies
have been able to identify reliable correlates of protection in
chronic HIV infection. Similar data have been reported for
individuals undergoing various SIT regimens (6, 24, 47). In the
TABLE 4. CD8 T-cell recognition of optimal epitopes within immunodominant regions of Gag and Nef a
Patient Immunodominant region Optimal epitope HLA Location(positions)
101 WEKIRLRPGGKKKYKL KIRLRPGGK A3 p17 (18–26)
----------R-R--- --------R
------------R--- RLRPGGKKK A3, B7 p17 (20–28)
------R-R
RPGGKKKYK B7 p17 (22–30)
------R--
WIILGLNKIVRMYS IILGLNKI A2, A3 p24 (266–273)
--M----------- -M------
GLNKIVRMY B15 p24 (269–277)
DCKTILKALGPAATLE KALGPAATL B15,Cw3 p24 (335–343)
102 WEKIRLRPGGKKKYK KIRLRPGGK A3 p17 (16–30)
--------------R RLRPGGKKK A3, B7 p17 (20–28)
RPGGKKKYK B7 p17 (22–30)
--------R
114 LKETINEEAAEWDRVHP ETINEEAAEW A25 p24 (203–212)
------D---------- ----D-----
IHSQRRQDILDLWIYHTQG IHSQRRQDI A24 Nef (101–109)
-Y--K--------V----- -Y--K----
RQDILDLWI B7 Nef (106–114)
--------V
QDILDLWIY B18 Nef (107–115)
-------V-
DILDLWIY Cw7 Nef (108–115)
------V-
119 LDRWEKIRLRPGGKKKYKL KIRLRPGGK A3 p17 (13–31)
-----------------R- RLRPGGKKK A3, B7 p17 (20–28)
RPGGKKKYK B7 p17 (22–30)
--------R
LVQNANPDCKTILKALG VQNANPDCK A3 p24 (323–331)
NPDCKTIL B8 p24 (327–334)
124 EKAFSPEVIPMFSAL KAFSPEVIPMF B57 p24 (162–172)
EVIPMFSAL Cw3 p24 (167–175)
a Autologous epitopes are in bold type.
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setting of SIT, while the overall HIV-specific T-cell response
has been observed to increase with repeated exposure to bursts
of autologous viral replication, neither the magnitude nor the
breadth of the HIV-specific CD8 T-cell response could be
correlated with levels of plateau pVL after SIT. Our data
suggest a similar pattern. In two individuals who maintained
consistently lower levels of pVL in the absence of ART, one
(patient 101) exhibited a high-frequency HIV-specific CD8
T-cell response directed against a broad array of Gag epitopes,
while the other (patient 114) developed a narrowly focused
response, predominantly to Nef. A third individual (patient
124) with a more modest reduction in viremia off ART exhib-
ited a low-frequency HIV-specific CD8 T-cell response that
was more narrowly targeted to Gag. Conversely, the individual
with the worst virological response in the absence of ART
(patient 103) exhibited the broadest antiviral CD8 T-cell re-
sponse, which targeted predominantly epitopes derived from
the Gag protein. Thus, in agreement with numerous SIT stud-
ies that concluded that there is rarely an immunologic or vi-
rological benefit to this type of therapy (5, 21, 23, 24), our data
suggest that the frequency and breadth of the HIV-specific
CD8 T-cell response observed in the absence of ART in
individuals with chronic infection are not necessarily benefi-
cially altered by prolonged periods of SIT with respect to
virological outcome.
Detailed sequence analysis of targeted HIV epitopes in our
cohort revealed little variation during the course of SIT and
the post-ART period. A higher level of variation suggests pos-
sible selection pressure exerted by CD8 T cells and attempts
by the virus to escape recognition. However, this was not ob-
served regardless of virological outcome off ART. Indeed,
when we examined CD8 T-cell recognition of autologous
HIV epitopes present during and after SIT in two virological
responders, we found that a high percentage of CD8 T cells
recognized multiple conserved epitopes in Gag (patient 101) or
Nef (patient 114) using distinct HLA-restricted class I alleles.
These observations suggest that separate HLA-restricted pop-
ulations of HIV-specific CD8 T cells may prevent viral escape
through the focused recognition of immunodominant epitopes
(39, 54). Additionally, the lack of viral evolution in the majority
of targeted immunodominant epitopes over time despite the
presence of strong CD8 T-cell responses may be due to a high
degree of sequence conservation necessitated by biological
constraints. The HLA A3-KK9 and -RK9 epitopes in Gag p17,
the HLA B15-GY9 epitope in Gag p24, and the RQDILDLW
IY(106-115) region in Nef have all been identified as being
conserved regions in HIV that elicit strong CD8 T-cell
responses (2, 4, 16, 19, 25, 27, 28, 55). Many of these epitopes
are more than 90% conserved among clade B sequences in the
Los Alamos Sequence Database, and some are highly
conserved across other clades, suggesting constraints on
sequence evolution within these regions.
Due to the limited predictive value provided by simple quan-
titative measures of the HIV-specific CD8 T-cell immune
reactivity, we sought to investigate whether the quality of the
response was a better indicator of viral replication kinetics in
the absence of ART. It is well established that CD8 T cells
primed to eliminate virus-infected targets are capable of a
multitude of functions that include various combinations of
cytolytic activity together with cytokine and chemokine expres-
sion. Previous reports suggested that individuals with progres-
sive HIV disease produce less TNF- and IL-2, while long-
term nonprogressors retain the ability to make both of these
antiviral cytokines within their HIV-specific CD8 T-cell pop-
ulations. In addition, the expression of MIP1, but not IFN-,
has been found to dominate the HIV-specific CD8 T-cell
response regardless of the targeted HIV antigen and the total
frequency of the response (13). When we tested the function-
ality of virus-specific CD8 T-cell populations in individuals
with good virological outcomes, we found that despite differ-
ences in the magnitudes and breadths of the total HIV-specific
response, these individuals maintained a higher level of func-
tion overall than did individuals with poorer outcomes. It re-
mains to be determined, however, if HIV-specific CD8 T-cell
functionality is a consequence of low levels of plasma viremia
or if these cells actively restrict viral replication. A detailed
analysis of the contribution of each individual functional re-
sponse within polyfunctional HIV-specific CD8 T-cell popu-
lations may elaborate the causal nature of host-virus interac-
tions. However, it is likely that CD8 T-cell functionality alone
cannot account for changes in the replication kinetics of virus
in the absence of therapy. Despite the small number of patients
and the inherent issues associated with the interpretation of
observational studies of humans, these data suggest that func-
tional attributes of the HIV-specific CD8 T-cell response
might be important correlates of virological outcome after
exposure to SIT regimens and could represent useful biological
parameters to measure in the clinical context.
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